Jun 03, 2026
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
Read more
Apr 29, 2026
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
Read more
Apr 02, 2026
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Read more
Mar 30, 2026
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
Read more
Mar 12, 2026
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
Read more
Displaying 1 - 10 of 20